Table 1.
Clinical characteristics of the patients
| Patient ID | Age/gender | Cancer | Previous chemotherapy | TNM cancer staging | ICI (number of cycles) | irAEs (grade) | Treatments | Clinical resolution |
| Patient 1 | 77/F | Merkel carcinoma | No | Stade IIA | Pembrolizumab (six cycles) | Myocarditis G2 Pericarditis |
None | Yes |
| Patient 2 | 79.6/M | Melanoma | No | Stage IV | First line: pembrolizumab (two cycles) Second line: ipilimumab and nivolumab (three cycles) | Myocarditis G3 Ocular myositis |
CS+infliximab | Yes |
| Patient 3 | 64.9/M | Melanoma | No | Stage IIIC | Pembrolizumab (two cycles) | Myocarditis (G3) Hepatitis (G3) Myositis (G2) |
CS+MMF+infliximab | Yes |
| Patient 4 | 57.7/M | Small cell neuro-endocrine carcinoma | Cisplatine–etoposide | Stage IIIB | Ipilimumab and nivolumab (two cycles) | Myocarditis (G3–G4) Ocular myositis |
CS+TCZ | Yes |
| Patient 5 | 66.3/M | Prostate adenocarcinoma | Taxotere and cabazitaxel | Stage IV | Nivolumab (one cycle) |
Myocarditis (G3–G4) Myositis |
CS+MMF+TCZ | Yes |
| Patient 6 | 64.9/M | Squamous cell anal carcinoma | Capecitabine–mytomycin | Recurrence (LN | Pembrolizumab (two cycles) | Myocarditis (G3) Hepatitis (G2) Myositis (G3) |
CS | Yes |
| Patient 7 | 84.6/M | Melanoma | No | Stage IV | Nivolumab (four cycles) | Myocarditis (G2) Myositis |
CS | Yes |
| Patient 8 | 87.7/M | Melanoma | No | Stage IV | First line: pembrolizumab (two cycles) Second line: ipilimumab and nivolumab (two cycles) |
Myocarditis (G3–G4) Myositis |
CS+TCZ | Yes |
| Patient 9 | 74.9/M | Hepatocellular carcinoma | No | Stage IV | Atezolizumab (four cycles) | Myocarditis (G2) Myositis |
CS | Yes |
| Patient 10 | 56/M | Melanoma | No | Stage IV | Ipilimumab and nivolumab (four cycles) | Myocarditis (G1) Colitis (G3) Acute interstitial nephritis |
CS+infliximab+TCZ | Yes |
| Patient 11 | 64.6/M | Melanoma | No | Stage IIIC | First line: nivolumab (16 cycles) Second line: ipilimumab and nivolumab (four cycles) |
Myocarditis (G1) Colitis (G3) Thyroiditis Hypophysitis |
CS+infliximab | Yes |
CS, corticosteroid; F, female; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; LN, lymph node; M, male; MMF, mycophenolate mofetil; TCZ, tocilizumab; TNM, tumour, node, metastasis.